Decreased cerebral blood perfusion in an NIDDM patient with an A-to-G mutation in the mitochondrial gene; a possible contribution to cognition deficits in diabetes mel!itus Dear Sir, In their review article on cerebral function in diabetes mellitus, Biessels et al. [1] described the influence of glycaemic control on cerebral function in this disease. They failed, however, to indicate the presence of cerebral dysfunction caused directly by mitochondrial abnormalities which are not the consequence of diabetic control. An A-to-G mutation at np 3243 of Letters to the editor the mitochondrial gene has been described as cosegregating with diabetes [2] . This mutation was originally identified in patients with MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) [3] , which is characteristic for its recurrent episodes of stroke. Patients with MELAS have peculiar computed tomography or magnetic resonance imaging findings of cerebral infarctions, none of which can be attributed to an occlusion of a single cerebral vessel. These findings are frequently observed in MELAS patients in the absence of diabetes or other diseases known to cause cerebral infarctions. The aetiology of these findings is unknown, but vascular abnormalities resulting from abnormal function of vascular mitochondria may play a role.
The A-to-G mutation at np 3243 also exists in about 1% of non-insulin-dependent diabetic (NIDDM) subjects [4] and is the most common genetic mutation found in diabetes. There- fore, mitochondrial dysfunction caused by mitochondrial gene alterations, including other mutations or deletions, may be present in more diabetic patients than have been described [4] . By screening 300 patients with NIDDM, we identified the A-G mutation at np 3243 in three patients, none of whom had cerebrovascular symptoms such as found in MELAS. In a 57-yearold male patient, however, only a slight elevation of hearing threshold was observed. Though he had experienced no stroke-like episodes nor clinical manifestations of new or old cerebral infarctions, the iodoamphetamine (IMP) single-photon emission computed tomography studies of his brain revealed decreased blood perfusion in bilateral frontal and lateral lobes (Fig. 1) . Figure 1 shows the cerebral perfusion scan after intravenous administration of 222.0 MBq of 123I-IMP (numbers correspond to chronological order). Low perfusion was apparent bilaterally in the frontal and parietal lobes of his brain. The blood perfusion pattern was apparently different from those observed in patients with asymptomatic multiple infarctions. These observations suggest that in patients with an A-G mutation in the mitochondrial genome, cerebral blood perfusion may be focally decreased, which may result in cognitive deficits. As Biessels et al. [1] pointed out, most of the knowledge of neurochemical changes in the diabetic brain is based on the findings of streptozotocin-or alloxan-induced diabetes. These agents inhibit mitochondrial function resulting in the impairment of insulin secretion [5] . In these animals, therefore, both agents may cause mitochondrial dysfunction in other organs such as brain and nerve. A part of the findings observed in these animal models may be attributed to mitochondrial dysfunction caused not by deleterious glycaemic control but by direct damage to the mitochondria by streptozo-1005 tocin or alloxan. Further studies are needed to understand the real involvement of metabolic status of diabetes and the direct mitochondrial function in the cerebral functions of diabetic patients. But our observation in an NIDDM patient with 3243 mutation suggests the importance of mitochondrial dysfunction in the aetiology of cerebral disorders in NIDDM.
Yours sincerely, M. Odawara, K. Tada, K. Yamashita
